Chlordiazepoxide; estrogens, esterified - Generic Drug Details

What are the generic drug sources for chlordiazepoxide; estrogens, esterified and what is the scope of patent protection?

Chlordiazepoxide; estrogens, esterified is the generic ingredient in three branded drugs marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for chlordiazepoxide; estrogens, esterified

US Patents:	0
Tradenames:	3
Applicants:	1
NDAs:	1
DailyMed Link:	chlordiazepoxide; estrogens, esterified at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for chlordiazepoxide; estrogens, esterified

N05BA	Benzodiazepine derivatives
N05B	ANXIOLYTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for chlordiazepoxide; estrogens, esterified

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	MENRIUM 5-2	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	MENRIUM 5-4	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	MENRIUM 10-4	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-006	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for chlordiazepoxide; estrogens, esterified

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	MENRIUM 10-4	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-006	Approved Prior to Jan 1, 1982
Roche	MENRIUM 5-4	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-004	Approved Prior to Jan 1, 1982
Roche	MENRIUM 5-2	chlordiazepoxide; estrogens, esterified	TABLET;ORAL	014740-002	Approved Prior to Jan 1, 1982

Chlordiazepoxide and Esterified Estrogens: Market Dynamics, Regulatory Status, and Financial Trajectory

Last updated: September 24, 2026

Chlordiazepoxide combined with esterified estrogens was a legacy menopausal-therapy product marketed in the United States under the Menrium name. Its commercial position has deteriorated to near-zero because the combination is no longer a meaningful branded market, its active ingredients are available separately, benzodiazepine prescribing has declined, and systemic estrogen therapy carries extensive safety restrictions. No reliable public source reports current product revenue, active commercial sales, or a continuing manufacturer for the fixed-dose combination.

The product’s economic value is therefore historical rather than current. Any residual opportunity would depend on niche reintroduction, not on established demand.

What is chlordiazepoxide and esterified estrogens?

Chlordiazepoxide is a long-acting benzodiazepine with anxiolytic, sedative, anticonvulsant, and muscle-relaxant properties. Esterified estrogens are a mixture of estrogen sulfate compounds, primarily estrone sulfate and equilin sulfate, used for systemic estrogen replacement.

The historical combination was designed to address menopausal symptoms together with associated anxiety or tension. The combination paired:

Component	Pharmacologic role	Current commercial context
Chlordiazepoxide hydrochloride	Anxiolytic benzodiazepine	Available as a generic capsule
Esterified estrogens	Systemic estrogen replacement	Available historically as Menest and related products; availability has narrowed
Fixed-dose combination	Menopausal symptoms plus anxiety	Legacy product with no material current market presence identified

Menrium was marketed in strengths that paired chlordiazepoxide with esterified estrogens. Historical product information identifies strengths including 5 mg chlordiazepoxide with 0.625 mg esterified estrogens and 10 mg chlordiazepoxide with 1.25 mg esterified estrogens.[1]

What was the original market for Menrium?

Menrium targeted postmenopausal women whose symptoms included hot flashes, vasomotor instability, nervousness, and tension. Its commercial logic reflected an earlier treatment model in which menopausal complaints and anxiety were frequently managed together with sedative medicines.

That model has weakened for four reasons:

1. Menopausal hormone therapy is now prescribed more selectively and at the lowest effective dose.
2. Benzodiazepine use is subject to stronger dependence, misuse, falls, cognitive impairment, and withdrawal concerns.
3. Estrogen therapy is increasingly differentiated by route, dose, and indication rather than combined with an anxiolytic.
4. Clinicians can prescribe each component independently, avoiding unnecessary exposure to the second drug.

The fixed-dose combination also created a dosing mismatch. A patient requiring estrogen replacement may not need chlordiazepoxide, while a patient requiring short-term anxiolytic therapy may not require systemic estrogen.

When did chlordiazepoxide and esterified estrogens lose exclusivity?

The combination appears to have lost meaningful commercial exclusivity decades ago. Menrium was an older product, and its original intellectual-property position would have expired long before the current patent era for pharmaceutical combinations.

No active Orange Book patent or regulatory exclusivity basis is identified for the discontinued chlordiazepoxide-esterified-estrogens combination in current public FDA listings.[2] The product’s competitive barriers therefore do not arise from surviving composition-of-matter protection.

The likely exclusivity chronology is:

Event	Approximate status
Original approval and commercialization	Legacy product, several decades old
Original patent protection	Expired
FDA exclusivity	Expired
Fixed-dose generic competition	No material current market identified
Present status	Discontinued or commercially inactive combination

Exact original patent numbers and expiration dates are not consistently presented in current public FDA product records. The economic conclusion is unchanged: any original patent protection is no longer relevant to market entry.

What is the FDA regulatory status of the combination?

The fixed-dose product does not have a meaningful current FDA commercial position. FDA’s Drugs@FDA and Orange Book resources distinguish between approved products, discontinued products, and products that remain listed without active commercial marketing.[2,3]

The principal regulatory issues are:

• systemic estrogen safety labeling;
• benzodiazepine dependence and withdrawal risk;
• age-related sedation and fall risk;
• lack of a contemporary therapeutic rationale for routine coadministration;
• limited evidence supporting long-term use of the fixed-dose combination.

Estrogen labeling includes warnings concerning endometrial cancer, cardiovascular events, stroke, venous thromboembolism, and breast cancer risk. The FDA requires boxed-warning language for systemic estrogen products and estrogen-progestin products.[4]

Chlordiazepoxide labeling carries warnings related to abuse, misuse, addiction, physical dependence, and potentially life-threatening withdrawal reactions. These warnings were strengthened across benzodiazepine products in 2020.[5]

What is the Orange Book status of chlordiazepoxide and esterified estrogens?

The Orange Book does not provide a current competitive framework comparable to that of an active branded drug with listed patents and pending Paragraph IV challenges.

The market should be analyzed as two separate ingredient markets:

Chlordiazepoxide

Chlordiazepoxide hydrochloride is available as a generic prescription benzodiazepine. Generic capsules have been marketed in multiple strengths, including 5 mg, 10 mg, and 25 mg, depending on manufacturer and product availability.[6]

Its principal indications include anxiety disorders, acute alcohol withdrawal, and preoperative apprehension. Demand is mature and largely generic.

Esterified estrogens

Esterified estrogens were marketed in oral tablet products, including Menest. Historical strengths included 0.3 mg, 0.625 mg, 1.25 mg, and 2.5 mg.[7] Market availability has been less stable than for common estradiol products.

Estradiol products dominate many contemporary hormone-therapy decisions because they are available in oral, transdermal, topical, and vaginal forms. Clinicians can select route and dose more precisely than with older esterified-estrogen products.

How many patents cover the product?

No active patent estate with commercial significance has been identified for the fixed-dose combination.

The relevant patent categories would have included:

Patent category	Current assessment
Chlordiazepoxide composition patent	Expired
Esterified-estrogen composition patent	Expired
Fixed-dose combination patent	No active protection identified
Formulation patent	No current enforceable barrier identified
Method-of-use patent	No current combination-specific protection identified
Manufacturing patent	No publicly evident barrier preventing separate-ingredient competition

The product’s main barriers are regulatory and commercial, not patent-based. A new entrant would need to establish an FDA approval pathway, demonstrate adequate quality and stability, address combination-product labeling, and justify the medical need for concurrent exposure to both ingredients.

What formulation patents protect the product?

No current formulation patent has been identified as protecting the historical combination. The product was an oral tablet, a dosage form with limited technical differentiation.

A modern reformulation could theoretically pursue:

• modified-release chlordiazepoxide;
• lower-dose estrogen delivery;
• separate-dose bilayer tablets;
• unit-dose packaging;
• pharmacokinetic control;
• abuse-deterrent benzodiazepine delivery.

Those features would require new patent filings and supporting clinical or pharmaceutical-development data. They would not restore the historical product’s exclusivity automatically.

A reformulation would also face a weak commercial proposition. The principal clinical reason for combining the ingredients has diminished, and separate generic prescribing is straightforward.

Are there Paragraph IV challenges or generic launch risks?

No active Paragraph IV litigation or pending generic challenge of material commercial relevance has been identified for the discontinued fixed-dose combination.[2,8]

The generic-launch risk is better described as substitution risk:

• generic chlordiazepoxide competes with the benzodiazepine component;
• estradiol and other estrogen products compete with the hormone component;
• clinicians can prescribe the components separately;
• insurers and pharmacy benefit managers have little reason to prefer a legacy combination.

If a company sought to reintroduce the product, an abbreviated new drug application would depend on the existence of a suitable reference listed drug and an FDA-recognized pathway. If no active reference product were available, the sponsor could face a more burdensome 505(b)(2) or new drug application strategy rather than a simple ANDA pathway.[9]

What litigation affects chlordiazepoxide and esterified estrogens?

No significant current patent litigation involving the fixed-dose combination is identified in the principal public FDA and federal litigation sources reviewed for this product category.

The broader legal environment is more important than product-specific litigation:

• estrogen manufacturers have faced litigation concerning breast cancer, cardiovascular injury, and other alleged hormone-therapy risks;
• benzodiazepine manufacturers face product-liability exposure involving dependence, withdrawal, sedation, and misuse;
• labeling and informed-consent issues can affect legacy combination products even when patent disputes are absent.

These risks increase the cost of relaunching a product that combines a systemic hormone with a controlled-substance-class anxiolytic.

How does the product compare with current menopausal therapies?

Product category	Primary use	Competitive position
Chlordiazepoxide plus esterified estrogens	Menopausal symptoms with anxiety	Legacy, commercially inactive
Oral estradiol	Systemic menopausal symptoms	Broad generic availability
Transdermal estradiol	Systemic menopausal symptoms with potentially lower thrombotic exposure than oral therapy	Strong contemporary use
Vaginal estrogen	Genitourinary symptoms	Targeted therapy, limited systemic exposure
Estrogen-progestin therapy	Menopausal symptoms in patients with a uterus	Established but safety-limited
Nonhormonal therapies	Vasomotor symptoms	Expanding alternatives
Generic chlordiazepoxide alone	Anxiety or alcohol withdrawal	Mature, low-margin generic market

The combination is disadvantaged because current practice favors indication-specific treatment. Estrogen is prescribed for menopausal symptoms, while anxiety is more often managed with psychotherapy, antidepressants, nonbenzodiazepine medicines, or short-term benzodiazepines selected independently.

What is the financial trajectory of the product?

No reliable standalone revenue series is publicly available for Menrium or the chlordiazepoxide-esterified-estrogens combination. The financial trajectory can therefore be assessed by market status rather than reported sales.

Historical phase

The product benefited from:

• limited competition in older menopause therapy;
• broad use of oral estrogen;
• routine use of benzodiazepines for anxiety and tension;
• physician preference for fixed-dose convenience.

Decline phase

Demand likely declined as:

• hormone-therapy prescribing became more risk-sensitive after the Women’s Health Initiative findings;
• estrogen labels incorporated stronger cardiovascular and cancer warnings;
• benzodiazepine dependence and geriatric-safety concerns became more prominent;
• generic component products became readily available;
• separate prescribing became the clinical norm.

The Women’s Health Initiative sharply changed the risk-benefit assessment of systemic hormone therapy after publication of findings involving conjugated equine estrogen and medroxyprogesterone acetate.[10] Although those data do not directly test esterified estrogens combined with chlordiazepoxide, they affected the broader systemic estrogen market.

Current phase

The current product has no identifiable meaningful revenue base. Any remaining prescriptions would represent legacy use, isolated pharmacy availability, or historical database carryover rather than a scalable branded franchise.

Which companies are challenging or competing with the product?

No company is publicly positioned as a direct challenger to the fixed-dose combination. Competition comes from separate products:

• generic chlordiazepoxide manufacturers;
• manufacturers of oral estradiol;
• manufacturers of transdermal estradiol patches and gels;
• suppliers of vaginal estrogen products;
• manufacturers of nonhormonal vasomotor-symptom therapies.

The competitive landscape is fragmented on the estrogen side and commoditized on the chlordiazepoxide side. That structure leaves little room for a premium fixed-dose combination.

What licensing deals or partnerships affect the product?

No significant current licensing transaction involving the chlordiazepoxide-esterified-estrogens combination has been identified. The product’s historical commercial rights are not a visible component of current pharmaceutical licensing activity.

A transaction involving the asset would likely be an acquisition of dormant regulatory rights, a product-file transfer, or a legacy trademark rather than a growth-oriented licensing deal. The principal asset value would depend on the existence of a usable FDA reference, manufacturing documentation, and recoverable market access.

What generic entry scenarios exist?

A future entrant would face three practical scenarios:

Scenario	Commercial result
Relaunch of the historical tablet	Low probability of meaningful uptake
New fixed-dose combination through 505(b)(2)	Higher development burden and limited differentiation
Separate generic or branded products	More commercially rational than combination relaunch

Manufacturing barriers are modest for conventional tablets. The harder issues are:

• sourcing and qualifying esterified-estrogen active pharmaceutical ingredient;
• demonstrating content uniformity for low-dose estrogen;
• controlling chlordiazepoxide potency and stability;
• meeting controlled-substance handling requirements;
• producing an acceptable stability package;
• supporting labeling for both estrogen and benzodiazepine risks.

How strong is the patent estate?

The patent estate is effectively weak or nonexistent from a current commercial perspective.

Factor	Assessment
Composition-of-matter protection	Expired
Combination patent protection	No active protection identified
Formulation protection	No active protection identified
Regulatory exclusivity	Expired
Brand value	Minimal
Manufacturing complexity	Moderate but manageable
Clinical differentiation	Weak
Litigation protection	None identified
Relaunch attractiveness	Low

The absence of patent protection does not create an attractive generic opportunity because the market itself is limited. A technically easy-to-manufacture product can still be commercially unattractive when demand is low and regulatory risk is high.

What geographic markets remain relevant?

The United States is the most important market for assessing FDA status, Orange Book listings, and historical Menrium commercialization. The same combination may have had different brand names, approval histories, or availability in other countries.

Global opportunity is constrained by:

• country-specific controls on benzodiazepines;
• different hormone-therapy standards;
• local withdrawal of older estrogen products;
• limited reimbursement for legacy combinations;
• differing requirements for fixed-dose combination justification.

No broad international growth market is evident from the public record.

Key Takeaways

• Chlordiazepoxide combined with esterified estrogens was a legacy menopausal product associated with the Menrium brand.
• The fixed-dose combination has no meaningful current commercial presence identified.
• Original patent and regulatory exclusivity have expired.
• No active Orange Book patent position or material Paragraph IV litigation has been identified.
• Generic chlordiazepoxide and separate estrogen products eliminate most of the combination’s pricing power.
• Systemic estrogen safety concerns and benzodiazepine dependence warnings materially weaken relaunch economics.
• The financial trajectory is best characterized as historical commercialization followed by decline and effective market exit.
• A new product would require regulatory redevelopment with limited clinical differentiation and low expected market demand.

FAQs

Is Menrium still available in the United States?

Menrium does not have a meaningful active commercial presence in current U.S. pharmaceutical markets. Historical listings may remain in drug databases, but those listings do not establish current distribution.

Is chlordiazepoxide a controlled substance?

Chlordiazepoxide is a benzodiazepine regulated as a controlled substance in the United States. Its use is subject to prescribing, dispensing, dependence, and withdrawal controls.

Are esterified estrogens the same as estradiol?

No. Esterified estrogens are a mixture of estrogen sulfate compounds, while estradiol products contain estradiol or an estradiol ester. They differ in composition, pharmacokinetics, labeling, and available dosage forms.

Could a company file an ANDA for the historical combination?

An ANDA would depend on the existence of an appropriate FDA reference listed drug and the ability to demonstrate pharmaceutical equivalence and bioequivalence. If the reference product is unavailable or unsuitable, a 505(b)(2) application may be more realistic.

Does the combination have biosimilar risk?

No. Biosimilar rules apply to biological products. Chlordiazepoxide and esterified estrogens are small-molecule drug substances, so the relevant competitive threats are generic and 505(b)(2) products, not biosimilars.

References

1. Roche Products, Inc. (n.d.). Menrium: Chlordiazepoxide hydrochloride and esterified estrogens product information. Historical prescribing information.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Estrogen and estrogen with progestin labeling information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers

5. U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov/drugs/drug-safety-and-availability

6. U.S. National Library of Medicine. (2024). Chlordiazepoxide hydrochloride prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

7. U.S. National Library of Medicine. (2024). Esterified estrogens prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

8. U.S. Food and Drug Administration. (2024). Paragraph IV drug product applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

9. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs

10. Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321